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ABSTR ACT: Tau proteins play a role in the stabilization of microtubules, but in pathological conditions, tauopathies, tau is modified by phosphorylation 
and can aggregate into aberrant aggregates. These aggregates could be toxic to cells, and different cell models have been used to test for compounds that might 
prevent these tau modifications. Here, we have used a cell model involving the overexpression of human tau in human embryonic kidney 293 cells. In human 
embryonic kidney 293 cells expressing tau in a stable manner, we have been able to replicate the phosphorylation of intracellular tau. This intracellular tau 
increases its own level of phosphorylation and aggregates, likely due to the regulatory effect of some growth factors on specific tau kinases such as GSK3. 
In these conditions, a change in secreted tau was observed. Reversal of phosphorylation and aggregation of tau was found by the use of lithium, a GSK3 
inhibitor. Thus, we propose this as a simple cell model to study tau pathology in nonneuronal cells due to their viability and ease to work with.
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Introduction
Tau is modified by phosphorylation in pathological conditions 
known as tauopathies. Then, phosphorylated tau can aggre-
gate into aberrant insoluble polymers called neurofibrillary 
tangles (NFTs).1 NFTs consist of paired helical filaments and 
straight filaments of tau and can be formed from all six iso-
forms of tau.2 In vitro, numerous kinases have been shown to 
phosphorylate tau, although the number that is physiologically 
relevant is significantly lower.3 Dephosphorylated tau has 
been demonstrated to promote microtubule assembly and is, 
therefore, tau in its natural, healthy state.4,5 The amount of 
NFTs in the brain has been shown to correlate with cognitive 
decline in diseases such as Alzheimer disease (AD).6 In some 
tauopathies such as AD, there is an increase not only in the 
amount of phosphorylated tau but, to a lesser extent, also in 
the amount of total tau.7
Among scholars, there is a debate whether NFTs 
themselves are toxic or, rather, if toxicity is caused mainly 
by the hyperphosphorylated tau.8,9 What is known is that 
NFTs are formed by hyperphosphorylated tau, but the pro-
cess by which aggregation occurs has yet to be described. 
Numerous factors have been shown to promote aggrega-
tion, but the initial trigger of aggregation is still unknown. 
Because phosphorylated tau is a structural feature of NFTs, 
it is possible that their existence in cells may trigger the 
tangle-forming process. Some mouse models have demon-
strated a link between phosphorylated tau and the ensuing 
tau aggregates.5,10
While NFTs are the most common products of tau aggre-
gation and are associated with many different tauopathies, 
other classes of tau aggregates do exist. Abnormally phos-
phorylated tau with four repeats can aggregate to form argyro-
philic grains and coiled bodies, as seen in argyrophilic grain 
disease.11 Hirano bodies, which are associated with various 
neurodegenerative diseases including AD, are intracellular 
aggregates containing actin, tau, and other microtubule-
associated proteins.12 Three-repeat isoforms of tau can accu-
mulate in spherical aggregations in limbic and cortical neurons 
in the form of Pick bodies.13
Although tauopathies comprise various forms of tau, 
it is evident that all tauopathies are characterized by the 
accumulation, phosphorylation, and aggregation of tau. This 
overexpression and accumulation of tau can also lead to release 
of tau to the extracellular medium, which is known to be toxic 
to cells.14,15
The goal of this study is to create a simple model to 
study tau pathology. This model will be a nonneuronal cell 
model expressing tau in high amounts, exemplifying the 
accumulation of tau. We hope to observe the modification 
of tau by phosphorylation and ultimately the formation of 
aggregates. If accomplished, we would have created a simple 
model emulating the three major characteristics of all tauopa-
thies, namely, accumulation, phosphorylation, and aggrega-
tion of tau. We propose to use human embryonic kidney 293 
(HEK293) cells due to their general stability, viability, and 
ease of transfection.
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Material and Methods
Materials. Antibodies are PHF-1, Tau-7.51, Tau-1, Tau-
12, GSK-3β, P-GSK3, and β-actin.
PHF-1 recognizes tau at the phosphorylated residues 
of serines 396 and 404 and was a kind gift from Dr. Peter 
Davies (Scotland, UK).16 Tau-7.51 is a generic tau marker as 
it recognizes all PHF core-derived tau, native soluble tau, 
and recombinant tau.17 The Tau-7.51 antibody was a kind gift 
from Dr. Claude Wischik (New York, USA). Tau-1 recog-
nizes tau protein when the serine residues 195, 198, 199, and 
202 are dephosphorylated.18 It was obtained from Chemicon. 
Tau-12 also detects total tau by binding to an epitope that lies 
between amino acids 9 and 18 on human tau. It was obtained 
from Abcam. GSK-3β antibody recognizes nonphosphory-
lated GSK3. It was obtained from transduction. P-GSK3 
antibody recognizes both GSK-3α phosphorylated at serine 
21 and GSK-3β phosphorylated at serine 9.19 It was obtained 
from Cell Signaling Technology. β-Actin is used as a loading 
control. It was obtained from Sigma-Aldrich.
Cell culture and transfection for model of tau expres-
sion in HEK293 cells. HEK293 cells were cultured in a sup-
plemented Dulbecco’s modified Eagle’s medium (DMEM) 
as previously described,20 supplemented with 10% fetal 
bovine serum, 2 mM glutamine, 1 mM piruvate, 100 U/mL 
penicillin, 100 U/mL streptomycin, and 0.2 mg/mL Zeocin 
in a humidified atmosphere of 5% CO2/95% air at 37°C. The 
supplemented DMEM without the serum or a slight modi-
fication of either [addition of lithium chloride (LiCl)] was 
used in some experiments. Transient transfection with three-
repeat tau was done as previously described.20 At varying time 
intervals after transfection, cells were harvested by scraping, 
washed in phosphate-buffered saline (PBS), resuspended 
and homogenized in buffer for Western blotting, or fixed 
for immunofluorescence analysis. HEK293 tau-expressing 
cells (expressing tau 3R isoform, a kind gift from Dr. Miguel 
Medina)20 in a stable manner were grown in DMEM with 
0.2 mg/mL Zeocin.
Sodium dodecyl sulfate polyacrylamide gel electro-
phoresis and Western blotting. Proteins for cell extracts 
(15 µg) were boiled at 100°C for five minutes to denature the 
proteins. Later, the samples were subjected to sodium dodecyl 
sulfate polyacrylamide gel electrophoresis on 10% resolving 
gels in tris-glycine buffer and transferred to a nitrocellulose 
membrane via electroblotting according to standard proce-
dures. Total amount of transferred proteins was determined 
by Ponceau S staining. All nitrocellulose membranes were 
blocked with a buffer comprising 5% nonfat powdered milk in 
PBS with 0.1% Tween-20. The membranes were then probed 
with the appropriate monoclonal antibodies to identify the 
fractionated proteins. The blots were subjected to chemilumi-
nescence and visualized.
Immunocytochemistry. Immunocytochemistry was 
performed as previously described.21 Briefly, cells fixed on 
crystals with 4% paraformaldehyde in PBS were washed and 
preincubated with PBS containing 0.1% Triton X-100 and 1% 
serum. Monoclonal primary antibodies were added, and the 
cells were incubated overnight. The cells were then washed 
with PBS and incubated with fluorescent secondary antibody 
conjugates. To visualize the nuclei, cells were stained with 
4′-6dianino-2-fenilindol (DAPI) (Molecular Probes). Slides 
were mounted with Fluoromount, and fluorescent images 
were captured using appropriate filters in a ZEISS vertical 
microscope Axioskop 2 Plus.
Data analysis. Quantification of immunoreactivity of 
tau bands obtained from Western blotting was obtained by 
densitometric scanning using a GS-800 calibrated densitome-
ter and Quantity One for quantification. All the analyses were 
performed using SPSS for Windows version 17.0. The ratios 
of protein levels among the treated samples to the controls are 
expressed as mean ± standard error of the mean, n = 3. The 
results were analyzed by Student’s unpaired t-test.
Results
Model. In the central nervous system, tau exists in six 
isoforms with either three or four repeats.5 HEK293 cells 
were transfected with three-repeat tau (3 + 0) that can be 
expressed under cytomegalovirus promoter to induce high 
constitutive expression of tau. Recent literature has demon-
strated that tau expressed in HEK293 cells can be modified by 
phosphorylation in these proliferating cells.22 This study aims 
to expand this knowledge by exemplifying that a model can be 
created to mimic the three factors for tau pathology, namely, 
accumulation, phosphorylation, and aggregation. This model 
is proposed to be HEK293 cells expressing tau. We propose 
that this model can be used to study compounds preventing 
tau pathology.
Transient transfection of 3 + 0 tau in HEK293 cells 
leads to tau phosphorylation. The goal of this experiment 
was merely to determine if HEK293 cells are able to express 
tau protein when transfected transiently with tau. In order 
to this, transient transfection assays were performed with 
varying quantities of tau (3 + 0) cDNA up to 2.0 µg, and 
tau expression was determined by subjecting the isolated 
proteins to Western blot analysis using the primary anti-
bodies PHF-1 and β-actin. PHF-1 is an antibody isolated 
from aggregated human tau isolated in Dr. Davies’ labora-
tory23 that could recognize phosphotau not only in disease 
but also in other states.24 Figure 1 depicts the results of the 
Western blot analysis. As can be seen, control HEK293 
cells do not express tau at all. Transiently transfected cells 
with tau are able to express phosphorylated tau (Fig. 1A), 
and this tau also aggregates, as seen by the elongated signal 
when the Western blot is exposed for a longer period of 
time (Fig. 1B). Knowing that HEK293 cells are capable of 
expressing Tau3R, HEK293 cells can be stably transfected 
with three-repeat tau as previously described (HEK293-
Tau3R),20 and this cell line was maintained and used for all 
future experiments.
Tau pathology 
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Time-course analysis of total and phosphorylated 
tau in stable HEK293-Tau3R cells. The behavior of tau 
expressed in a stable manner (HEK293-Tau3R) was tested 
during cell growth. HEK293-Tau3R cells were placed in 
dishes (104 cells/dish), and after 12 and 24 hours, levels of tau 
protein were analyzed by Western blot. Figure 2 shows that 
tau protein levels (using 7.51 antibody) as well as phosphory-
lated tau (modified at the site recognized by PHF-1 antibody) 
are maintained during cell proliferation.
Depletion of serum in cultured cells causes changes 
in GSK3 phosphorylation. Cells were incubated in two dif-
ferent conditions: (1) nutrient-rich medium with serum for 
48 hours (+) and (2) nutrient-rich medium with serum for 
24 hours, medium removed and changed to serum-depleted 
medium for 24 hours (without serum) (-). Figure 3 depicts 
the Western blot results using primary antibodies to detect 
GSK-3β and phosphorylated GSK3 in inhibitory domains. 
The results indicate there are less P-GSK3 and more active 
(unphosphorylated) GSK3 in the (-) condition, which should 
lead to higher levels of phosphorylated tau. These results are 
what one would expect with respect to GSK3 phosphoryla-
tion, given the inhibition diagram shown in Figure 3A.
Stable overexpression of tau in HEK293 cells causes 
secretion of tau to the extracellular milieu. Once again, 
HEK293-Tau3R cells were grown in regular medium for 
24 hours. In half of the cohort, the medium was removed 
and replenished (+), and in the other half, the medium was 
removed and changed for a serum-depleted medium lacking 
growth factors (-). After a second 24 hours, the supernatant 
of each cohort was collected. The supernatants were then 
subjected to Western blot analysis using the Tau-12 primary 
?????
β?????? ?????????????????? ?????
β?????? ????????????????????????? ??? ??????? ???? ?
Figure 1. HEK293 cells transiently transfected with three-repeat tau are capable of expressing phosphorylated tau. (A) Western blot analysis of 
intracellular presence of phosphorylated tau (pHf-1) and total cell count (β-actin) in untransfected (control) HEK293 cells (left) and HEK293 cells 
transiently transfected with three-repeat isoform tau (tau). no phosphorylated tau is present in control cells, while phosphorylated tau can be seen 
in transfected cells. (B) longer exposure of Western blot analysis from (A). it is evident that the phosphorylated tau aggregates, as seen by the long, 
elongated signal. ?? ??????????? ?? ?????????????????????????? ???? ?????? ?? ?? ?????????????? ????????????β??????
Figure 2. total tau expression is maintained during cell proliferation in 
a time-dependent manner in stable transfected HEK293-tau3r cells. 
(A) Growth of HEK293-tau3r cells showing their proliferation rate 
after 12 and 24 hours after platting. Western blot analysis to test for the 
presence of total tau protein, using abtau 7.51, and phosphorylated tau, 
using abpHf-1. (B) Quantification, by densitometry, of the Western blot 
shown in (A). overall, it can be seen that the increase in tau amount 
correlates with the number of HEK293-tau3r cells.
Houck et al
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antibody to detect the presence of total tau (Fig. 4). The results 
in Figure 4 demonstrate that tau is secreted to the extracel-
lular milieu in a nutrient-rich (+) medium, whereas tau is not 
secreted in a serum-depleted medium. These results align with 
the previous literature, which shows that tau overexpression 
leads to its secretion.15
Levels of phosphorylated tau change in the presence 
or absence of serum. HEK293-Tau3R cells were again grown 
in vitro in either regular medium (+), which had serum, or a 
serum-depleted medium (-). At 12 hours, cells were collected 
and subjected to immunofluorescent staining and analyzed 
by optical microscopy, as depicted in Figure 5. Primary anti-
bodies were used to detect phosphorylated tau (PHF-1) and 
dephosphorylated tau (Tau-1). It is clear that phosphorylation 
of tau is higher when cells are grown in the serum-depleted 
medium. The opposite is the case for dephosphorylated tau. 
Dephosphorylated tau is present in highest amounts when 
cells are grown in a regular nutrient-rich medium (Fig. 5). 
To confirm this observation, a Western blot analysis was 
performed.
In the absence of serum, tau is phosphorylated by 
GSK-3β. Western blot was probed with the monoclonal pri-
mary PHF-1 antibody to detect tau phosphorylation. Figure 6 
depicts the Western blot results, confirming the results shown 
in Figure 5, showing higher total tau levels of phosphory-
lated tau in the (+/-) condition than in the (+/+) condition. 
This suggests that, in this model, tau is indeed phosphory-
lated likely by GSK3. Additionally, traces of aggregate tau 
can be seen in the (+/-) condition by slight existence of signal 
between the 52 and 76 kDa markers.
Intracellular aggregates increase when cells are grown 
in a serum-depleted medium in a time-dependent manner. 
The earlier experiments were combined and modified to assess 
the formation of tau aggregates in a time-dependent manner. 
HEK293-Tau3R cells were again grown in vitro in either 
regular medium (+), which had serum, or a serum-depleted 
medium (-). Cells were collected at 1, 12, and 24-hour time 
points and subjected to Western blot analysis using the pri-
mary PHF-1 antibody, which detects phosphorylated tau 
(Fig.  7). At 24 hours, it is evident that tau aggregates have 
been formed as shown by the elongated signal above the white 
line in Figure 7. There is a significant increase in aggregates 
at 24 hours compared with cells grown in serum-depleted 
medium.
? ???????????????????????????????? ?????? ??? ?????????????? ?????????? ????????????????????????αβαβ????? ??? ???
Figure 3. Growth factors in serum inhibit GsK3 through phosphorylation, and cells with depleted serum display a decrease in p-GsK3. (A) in the 
presence of serum, GsK3 is phosphorylated. in a medium with serum removed, growth factors such as insulin are not present to phosphorylate 
GsK3 and unphosphorylated GsK3 is now free to phosphorylate substrates such as tau. (B) it can be seen that overall levels of GsK3 remain the 
same in both growth conditions. However, there is an increase in phosphorylated GsK3 (bands halfway between the 38 and 52 kDa markers) in 
cells in the (+, with serum) condition when compared with the (-, without serum) condition. this indicates that there is less p-GsK3 and more active 
(unphosphorylated) GsK-3β in the (-) condition, which should lead to higher levels of phosphorylated tau. (C) Densitometric analysis of overall levels 
of P-GSK3/GSK3 confirms that P-GSK3 is higher in the (+) condition relative to overall GsK-3β, compared with the (-) condition. *P , 0.05 versus 
medium with serum.
??????????????????????? ??? ??? ??????
Figure 4. in culture, HEK293-tau3r cells secrete tau to the extracellular 
milieu. Western blot analysis of aliquots of the cell media (supernatant) 
when HEK293-tau3r cells are grown in either the presence (+) or 
absence (-) of serum. it is clear that in the (+) conditions, tau can be 
detected in the serum, indicating that it is secreted from within the cells. 
in the (-) condition, no tau is detected, indicating an inhibition in this 
secretion.
Tau pathology 
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Introduction of lithium results in a decrease in 
tau phosphorylation and a decrease in tau aggregation. 
Similar to the previous experiments, two sets of HEK293-
Tau3R cells were again grown in vitro for 24 hours in a 
regular medium. After 24 hours, the medium of the first 
group of cells was removed and changed for serum-depleted 
medium (-). In the second group of cells, the medium was 
also removed and changed for serum-depleted medium, but 
LiCl (20 mM) was added to the medium as well. Lithium 
is known to be an inhibiting agent of GSK3 in several 
??????? ?????????????? ?????????????????????????????????
Figure 5. levels of dephosphorylated tau decrease as levels of phosphorylated tau increase. Dapi staining is depicted in blue and primary antibodies 
(either phosphorylated or dephosphorylated tau) in red. at 12 hours, in the presence of serum, there are high levels of dephosphorylated tau (tau 1—
bottom left panel) relative to phosphorylated tau (pHf-1—top left panel). in contrast, when cells are grown in serum-depleted medium, levels of 
phosphorylated tau increase (pHf-1—top right panel), and levels of dephosphorylated tau decrease (tau 1—bottom right panel).?? ????? ??? ??? ????? ??? ????????β?????? ???????????? ???????????????????????????? ?
Figure 6. tau phosphorylation increases in cells in a serum-depleted medium. (A) Western blot analysis of tau phosphorylation (pHf-1) when HEK293-
tau3r cells are grown in a nutrient-rich medium for 48 hours (+). then, the medium was removed in some samples and changed to serum-depleted 
medium for another additional 24 hours (-). an increase in levels of phosphorylated tau can be seen in the (-) condition. (B) Densitometry analysis 
of phosphorylated tau of the Western blot bands from (A). there is an increase in phosphorylated tau in the (-) condition, relative to the (+) condition. 
*P , 0.05 versus medium with serum.
Houck et al
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ways, including directly or through complex signaling 
networks.25–27 This is depicted in Figure 8A. The addition of 
lithium should inhibit GSK3 and disallow for the phosphor-
ylation that the lack of nutrients would generally provide. 
The Western blot results in Figure 8B and C confirm this. 
The addition of lithium to the cell medium nearly eradicates 
the tau phosphorylation that would have been induced by 
the serum-depleted medium.
From these results, we can make several inferences based 
on some of our former experiments. As can be seen, tau 
pathology in cells grown in the medium with lithium should 
and does emulate tau changes in cells grown in normal (+) 
medium because lithium may have a similar inhibitory effect 
on GSK3 as the nutrients in the serum (insulin or related fac-
tors) do (Fig. 8). Based on these results, it can be assumed that 
lithium may cause a decrease in tau aggregation due to the 
fact that tau phosphorylation may lead to its own aggregation 
(Fig. 7).
Discussion
Tau proteins are integral to cell microtubule stabilization 
under healthy conditions, but in pathological conditions, 
tauopathies, tau becomes phosphorylated and can aggregate 
into aberrant polymers such as NFTs, which are found in AD. 
The goal of this project was to create a simple nonneuronal 
model to study tau pathology using HEK293 cells transfected 
with three-repeat tau.
Currently, while several animal models of AD exist, 
no stable cell line has been established to quickly test tau 
pathology. In our work, we transfected HEK293 cells with 
three-repeat tau and used Western blot analysis and immu-
nocytochemistry to investigate tau phosphorylation in these 
cells. Three-repeat tau was used because we were unable to 
successfully produce a stable transfection expressing four-
repeat tau in the same conditions of protein overexpression. 
A possible explanation is that Tau4R can bind to microtubules 
with a higher affinity, thus stabilizing the cells and impeding 
breakdown of microtubule polymers during interphase.28,29
A likely origin of the increase in tau phosphorylation 
observed in pathological conditions in neurons could be a 
decrease in the nutrients supplied by the surrounding non-
neuronal cells. In cell culture, these nutrients are mainly sup-
plied to the cells by the addition of serum to the cell medium. 
Because of this, we altered the medium in which the cells 
?????
?????
?? ???????????
?? ???????????
? ? ? ? ? ?
? ? ? ? ? ??????β?????? ??????
????????????????????????????????? ????????? ?
Figure 7. tau aggregation increases in a time-dependent manner, and even more when cells are grown in a serum-depleted medium. (A) Western blot 
analysis of intracellular presence of phosphorylated tau (pHf-1) in HEK293-tau3r cells at 1, 12, and 24 hours in regular medium with serum (+) and a 
medium with serum removed (-). aggregated tau can be seen at the 12 and 24-hour time points by the elongated signal above the white line. it is most 
noticeable in the cells grown in serum-depleted medium. (B) Densitometry analysis of aggregated phosphorylated tau of the Western blot bands from (A). 
There is a significant increase (*P , 0.05) in aggregates at 24 hours compared with cells grown in serum-depleted medium.
Tau pathology 
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were grown by removing the growth factors and observing the 
changes in phosphorylation. Because specific kinase inhibitors 
such as lithium can prevent phosphorylation, we tested the 
effect of lithium addition to the cell medium on tau phosphor-
ylation. If lithium decreased tau phosphorylation, we propose 
that this model could be extrapolated for other compounds 
and kinase inhibitors that affect tau phosphorylation.
Overall, we were able to develop a nonneuronal cell model 
expressing tau that gives rise to tau phosphorylation and ulti-
mately tau aggregation in the cells. As hypothesized, in this 
model, decreased factors (insulin and related factors) lead to 
the increase in tau phosphorylation and aggregation, as it is 
seen in AD. On the other hand, lithium, a GSK3 inhibitor, 
has been shown to inhibit this induced tau phosphorylation. 
This model has also been able to reproduce the secretion of 
tau from within the cells to the extracellular milieu, as has 
been seen in previous study.15 Recent literature has indicated 
that when tau is present outside the cells, it is more toxic in its 
dephosphorylated state; so, this model could be used for future 
experiments studying this phenomenon.30,31
Because NFTs are universally present in AD and 
many other tauopathies, this model can be used for more 
generalized large-scale studies. While we have shown that 
the model demonstrates the three key factors of tauopathies, 
namely, accumulation, aggregation, and phosphorylation, we 
have also shown that the model effectively replicates GSK3’s 
effects on tau via analysis of GSK3 itself as well as lithium, 
a GSK3 inhibitor. Therefore, this model can also be used to 
detect GSK3 inhibitors and potentially other proteins both 
upstream and downstream that could be involved in tau 
phosphorylation.
Future research is necessary to establish a clear link 
between tau aggregation and its phosphorylation. There may 
be factors upstream of tau aggregation, but downstream 
of GSK-3β phosphorylation, which may play a role in the 
forming of NFTs. It would also be prudent to further analyze 
how exactly tau phosphorylation and aggregation directly 
affects tau secretion. Overall, we believe this HEK293-
Tau3R cell line to be a simple yet effective model to study tau 
pathology.
??? ??? ???????????????????????????????????????? ??
?? ???? ?????????? ??????? ????????????????? ??? ??? ??????????????????β?????? ??????
Figure 8. introduction of lithium to the cell media nearly eradicates intracellular tau phosphorylation. (A) lithium itself is an inhibitor of GsK3. therefore, 
its presence should deactivate GsK3 and disallow for tau phosphorylation. this is similar to GsK3 being inhibited by phosphorylation when cells are 
grown in a nutrient-rich medium. (B) Western blot analysis of intracellular presence of phosphorylated tau (pHf-1), total tau (ab7.51), and total cell count 
(β-actin). it is clear that the introduction of lithium (20 mm) to the cell medium blocks the tau phosphorylation that was induced by the lack of growth 
factors in the serum-depleted medium. (C) Densitometry analysis of phosphorylated tau of the Western blot bands from (B). *P , 0.05.
Houck et al
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